Document is current

Article History

Received: 5 May 2020

Accepted: 11 October 2020

First Online: 2 November 2020

Ethics approval and consent to participate

: This trial was registered with the US National Institutes of Health (ClinicalTrials.gov identifier: NCT01790932, NCT01629615). All patients provided written informed consent before the initiation of any study-related procedures or treatments.

: Not applicable.

: C.S. reports the following personal financial interests: C.S. has served as consultant, participated in advisory boards or received travel grants from AstraZeneca, Celgene, Daiichi Sankyo, Eisai, F. Hoffmann-La Roche Ltd., Genomic Health, Merck, Sharp and Dhome España SA, Novartis, Pfizer, Philips Healthwork, Pierre Fabre, prIME Oncology, Puma, Synthon, and Sanofi Aventis. C.S. reports the following institutional financial interests, paid directly to Institution: AstraZeneca, Daiichi Sankyo, Eli Lilly and Company, Genentech, Immunomedics, Macrogenics, Merck, Sharp and Dhome España S.A., Novartis, Pfizer, Piqur Therapeutics, Puma, Roche, Synthon and Zenith Pharma.R.B-S. has served as an advisor/consultant to Eli Lilly and Roche and has received honoraria from Eli Lilly, Roche, Bristol-Myers Squib, Novartis, Pfizer, and travel, accommodations, or expenses from Roche.L.C.C. is a founder and member of the SAB and holds equity in Agios Pharmaceuticals and Petra Pharmaceuticals, companies developing drugs for treating cancer. The laboratory of L.C.C also receives funding from Petra.D.B.S. has consulted with and received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Illumina, and Vivideon Therapuetics.B.B. has participated in advisory boards for MSD, Mylan, Roche, and Novartis.V.S. has received non-commercial support from Novartis.C.A. serves or has served as an advisor to Novartis, Lilly, Sanofi, RADIUS, ABBVIE, TAIHO Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, Athenex, and Daiichi Sankyo. C.A. receives or has received research grant support from Pfizer, Lilly, RADIUS, Bayer, Takeda, PUMA Biotechnology, and Symphogen. C.A. holds stock options in Provista and Y-TRAP and serves in the Scientific Advisory Board of the Komen Foundation.N.U.L. receives or has received research support paid directly to the Institution from Genentech, Pfizer, Merck, and Seattle Genetics. N.U.L. has served as a consultant or participated in advisory boards for Puma, Seattle Genetics, Daiichi Sankyo, Denali Therapeutics, and California Institute for Regenerative Medicine. N.U.L. has received travel expense reimbursement from Puma and Seattle Genetics.All other authors declare no relevant conflicts of interest.